Aripiprazole in the treatment of Huntington’s disease: a case series
Andrea Ciammola1, Jenny Sassone1, Clarissa Colciago1, Niccolò E Mencacci1, Barbara Poletti1, Andrea Ciarmiello2, Ferdinando Squitieri3, Vincenzo Silani11Department of Neurology and Laboratory of Neuroscience, “Dino Ferrari” Centre, University of Milan Medic...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2008
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5e0f015722d84d4286d5f215af163d78 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:5e0f015722d84d4286d5f215af163d78 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:5e0f015722d84d4286d5f215af163d782021-12-02T00:31:16ZAripiprazole in the treatment of Huntington’s disease: a case series1176-63281178-2021https://doaj.org/article/5e0f015722d84d4286d5f215af163d782008-11-01T00:00:00Zhttp://www.dovepress.com/aripiprazole-in-the-treatment-of-huntingtonrsquos-disease-a-case-serie-a2630https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Andrea Ciammola1, Jenny Sassone1, Clarissa Colciago1, Niccolò E Mencacci1, Barbara Poletti1, Andrea Ciarmiello2, Ferdinando Squitieri3, Vincenzo Silani11Department of Neurology and Laboratory of Neuroscience, “Dino Ferrari” Centre, University of Milan Medical School – IRCCS Istituto Auxologico Italiano, Milano, Italy; 2Unit of Nuclear Medicine, S. Andrea Hospital, La Spezia, Italy; 3Neurogenetics Unit, IRCCS Neuromed, Pozzilli (IS), ItalyObjectives: The aim of the study was to describe the effects of aripiprazole, a new atypical antipsychotic drug that acts as a partial dopamine agonist on motor, behavioral and cognitive functions in patients with genetically confirmed Huntington’s disease (HD).Methods and results: Three HD patients were evaluated for Unified Huntington Disease Rating Scale part I and II and Beck Depression Inventory at baseline, after two months and one-year treatment. Aripiprazole effectively controlled involuntary movements and psychiatric symptoms, with effects on cognitive functions.Conclusions: Our case reports suggest that aripiprazole is well tolerated, remarkably improving some of the motor and behavioral symptoms in patients affected by HD. Randomized, controlled, long-term studies are warranted.Keywords: Huntington’s disease, aripiprazole, treatment, chorea Andrea CiammolaJenny SassoneClarissa ColciagoNiccolò E MencacciBarbara Polettiet alDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 1-4 (2008) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Andrea Ciammola Jenny Sassone Clarissa Colciago Niccolò E Mencacci Barbara Poletti et al Aripiprazole in the treatment of Huntington’s disease: a case series |
| description |
Andrea Ciammola1, Jenny Sassone1, Clarissa Colciago1, Niccolò E Mencacci1, Barbara Poletti1, Andrea Ciarmiello2, Ferdinando Squitieri3, Vincenzo Silani11Department of Neurology and Laboratory of Neuroscience, “Dino Ferrari” Centre, University of Milan Medical School – IRCCS Istituto Auxologico Italiano, Milano, Italy; 2Unit of Nuclear Medicine, S. Andrea Hospital, La Spezia, Italy; 3Neurogenetics Unit, IRCCS Neuromed, Pozzilli (IS), ItalyObjectives: The aim of the study was to describe the effects of aripiprazole, a new atypical antipsychotic drug that acts as a partial dopamine agonist on motor, behavioral and cognitive functions in patients with genetically confirmed Huntington’s disease (HD).Methods and results: Three HD patients were evaluated for Unified Huntington Disease Rating Scale part I and II and Beck Depression Inventory at baseline, after two months and one-year treatment. Aripiprazole effectively controlled involuntary movements and psychiatric symptoms, with effects on cognitive functions.Conclusions: Our case reports suggest that aripiprazole is well tolerated, remarkably improving some of the motor and behavioral symptoms in patients affected by HD. Randomized, controlled, long-term studies are warranted.Keywords: Huntington’s disease, aripiprazole, treatment, chorea |
| format |
article |
| author |
Andrea Ciammola Jenny Sassone Clarissa Colciago Niccolò E Mencacci Barbara Poletti et al |
| author_facet |
Andrea Ciammola Jenny Sassone Clarissa Colciago Niccolò E Mencacci Barbara Poletti et al |
| author_sort |
Andrea Ciammola |
| title |
Aripiprazole in the treatment of Huntington’s disease: a case series |
| title_short |
Aripiprazole in the treatment of Huntington’s disease: a case series |
| title_full |
Aripiprazole in the treatment of Huntington’s disease: a case series |
| title_fullStr |
Aripiprazole in the treatment of Huntington’s disease: a case series |
| title_full_unstemmed |
Aripiprazole in the treatment of Huntington’s disease: a case series |
| title_sort |
aripiprazole in the treatment of huntington’s disease: a case series |
| publisher |
Dove Medical Press |
| publishDate |
2008 |
| url |
https://doaj.org/article/5e0f015722d84d4286d5f215af163d78 |
| work_keys_str_mv |
AT andreaciammola aripiprazoleinthetreatmentofhuntingtonamprsquosdiseaseacaseseries AT jennysassone aripiprazoleinthetreatmentofhuntingtonamprsquosdiseaseacaseseries AT clarissacolciago aripiprazoleinthetreatmentofhuntingtonamprsquosdiseaseacaseseries AT niccolampograveemencacci aripiprazoleinthetreatmentofhuntingtonamprsquosdiseaseacaseseries AT barbarapoletti aripiprazoleinthetreatmentofhuntingtonamprsquosdiseaseacaseseries AT etal aripiprazoleinthetreatmentofhuntingtonamprsquosdiseaseacaseseries |
| _version_ |
1718403676946563072 |